TearScience, a medical device manufacturer based in Morrisville, North Carolina, announced that it was able to secure $70 million in debt financing for the commercialization of its dry eye treatment technology. According to a press release by the company, the debt financing was backed by HealthCare Royalty Partners, a Connecticut investment firm founded in 2007.
The latest cash commitment follows a 2010 Series C financing round for $44.5 million. This earlier financing round was led by General Catalyst Partners, Investor Growth Capital, De Novo Ventures, Essex Woodlands Health Ventures, Quaker Bioventures and Spray Ventures.
In its press release, the company detailed how its dry eye technology worked. The LipiFlow is an ocular thermal pulsation device that helps to clear a patient’s blocked meibomian glands. This helps improve lipid flow and can restore the natural tear film found on the surface of the eye. The device also includes the LipiView Ocular Surface Interferometer. The Interferometer measures the thickness of the lipid layer found in the tear film of the eye.
- Linearity Measurements for MEMS Pressure Sensors - Supplier Resource
- Dual Die Compensation for MEMS Pressure Sensors - Supplier Resource
- Special Considerations for Mounting and Handling Pressure Sensors - Supplier Resource
- Special Kind of Plastic V3 - Video
- Visimobile v6 - Video
- Corporate Video - Video